An audit of the effect of SGLT2 inhibitor cessation in a pre-admission clinic before and after Australian Diabetes Society guidelines

Prishila Fookeerah; Henry Law; Farheen Ali; Katherine Chatten; Claire Kim; Ngai Wah Cheung

doi:10.1111/imj.15366

An audit of the effect of SGLT2 inhibitor cessation in a pre-admission clinic before and after Australian Diabetes Society guidelines

Intern Med J. 2021 Jun;51(6):980-983. doi: 10.1111/imj.15366.

Authors

Prishila Fookeerah¹, Henry Law², Farheen Ali², Katherine Chatten², Claire Kim², Ngai Wah Cheung^{1

3}

Affiliations

¹ Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia.
² Department of Anaesthesia and Perioperative Medicine, Westmead Hospital, Sydney, New South Wales, Australia.
³ Faculty of Medicine, The University of Sydney, Sydney, New South Wales, Australia.

PMID: 34155765
DOI: 10.1111/imj.15366

Abstract

Perioperative ketoacidosis is an important adverse event related to the use of sodium glucose co-transporter 2 inhibitor (SGLT2i). We compared perioperative outcomes in patients on SGLT2i, before and after protocolised pre-operative cessation of the drug. There were no cases of clinically detected diabetic ketoacidosis in the 96 patients included in the study. Withdrawal of SGLT2i did not appear to alter significantly pre-operative glycaemia.

Keywords: SGLT2 inhibitor; diabetic ketoacidosis; euglycaemic ketoacidosis; perioperative; sodium-glucose co-transporter 2 inhibitor; surgery.

MeSH terms

Australia / epidemiology
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Diabetic Ketoacidosis* / chemically induced
Diabetic Ketoacidosis* / diagnosis
Diabetic Ketoacidosis* / epidemiology
Humans
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors